Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAIB-TACE for hepatocellular carcinoma beyond the up-to-7 criteria
jRCTs031200334Completed
- Sponsor
- Japan Society for the Promotion of Science
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of cisplatin in hepatocellular carcinoma (HCC), sponsored by Japan Society for the Promotion of Science. Primary endpoint: Primary efficacy endpoint. Started Mar 2021; status: completed.
02
Drugs
cisplatin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCTs031200334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200334.